Prasterone vs Vaginal Estradiol: Which Treats GSM Better?

What Is Genitourinary Syndrome of Menopause and Why Treat It Locally?

Genitourinary syndrome of menopause (GSM) affects an estimated 50 to 84 percent of postmenopausal women, yet fewer than 25 percent receive any treatment, according to a position statement from the Menopause Society (formerly NAMS) [1]. The syndrome covers vaginal dryness, burning, irritation, painful intercourse (dyspareunia), urinary urgency, and recurrent urinary tract infections. All of these symptoms arise from the same root cause: estrogen and androgen deficiency in urogenital tissues.

Local therapy targets the vagina, vulva, and urethra directly. Systemic hormone therapy (oral or transdermal estradiol) raises circulating estrogen throughout the body and can improve hot flashes, bone density, and mood. Local therapy raises hormone levels in the tissue where the problem exists while keeping blood concentrations near the postmenopausal range. The American College of Obstetricians and Gynecologists states: "For women with genitourinary symptoms only, local vaginal therapy is preferred over systemic treatment because it achieves the needed tissue effect with less systemic absorption" [2].

Prasterone and vaginal estradiol are the two most-prescribed local options in the United States. They differ in their active molecule, mechanism of action, regulatory history, and practical cost, but both are supported by randomized controlled trial data showing improvements in the three FDA-designated co-primary endpoints for GSM studies: most bothersome symptom severity, percent superficial cells on vaginal cytology, and vaginal pH.

How Each Drug Works

Prasterone delivers dehydroepiandrosterone (DHEA) directly into vaginal tissue. Once inside the cell, intracellular enzymes convert DHEA to both estrogen and androgen locally. Testosterone and dihydrotestosterone act on vaginal smooth muscle and collagen, while locally produced estradiol acts on epithelial estrogen receptors. Because the conversion happens intracellularly, circulating estradiol and testosterone levels remain at or below the postmenopausal reference range [3]. The FDA reviewed serum hormone data from the ERC-230 trial and confirmed that 6.5 mg nightly prasterone did not raise systemic estradiol above baseline in postmenopausal women [4].

Vaginal estradiol works more directly. The estradiol molecule in the cream, tablet, or ring diffuses across the vaginal epithelium and binds estrogen receptors in the lamina propria, stimulating glycogen production, lactobacillus growth, and collagen synthesis. A small fraction absorbs systemically; the 4-mcg Vagifem/Yuvafem tablet was specifically engineered to reduce that fraction compared to the older 10-mcg tablet. In the REJOICE trial, 4-mcg vaginal estradiol produced serum estradiol levels within the postmenopausal range (below 20 pg/mL) in most participants at steady state [5].

The practical difference: prasterone provides both estrogenic and androgenic signaling inside vaginal cells without raising serum estrogen. Vaginal estradiol provides estrogenic signaling only, with a minor but measurable rise in serum estradiol.

Efficacy Data: Head-to-Head and Phase 3 Trials

No published randomized trial has placed prasterone and vaginal estradiol in the same study arm, so comparisons rely on independent phase 3 datasets with shared FDA endpoints.

Prasterone (ERC-230, N=557). After 12 weeks, prasterone 6.5 mg nightly reduced the most bothersome symptom score by 1.42 points on a 0-to-3 scale vs. 0.85 for placebo (P<0.001). Superficial cells rose from 1.1 percent to 8.7 percent in the active group vs. 1.3 percent with placebo. Vaginal pH dropped from 6.2 to 5.5 vs. a drop of only 0.1 in the placebo group [3]. A 52-week open-label extension confirmed maintained benefit with no accumulation of systemic hormone levels [6].

Vaginal estradiol 4 mcg (REJOICE, N=764). At 12 weeks, the 4-mcg insert reduced the most bothersome symptom score by 1.6 points vs. 1.1 for placebo (P<0.001). Superficial cells increased from 1 percent to 14.6 percent in the active arm. Vaginal pH fell from 6.3 to 5.0 [5]. The degree of superficial cell restoration was numerically larger for vaginal estradiol 4 mcg than for prasterone in these separate studies, a pattern consistent with pure estrogenic stimulation of epithelial maturation.

What does this mean clinically? Both drugs clear the FDA bar for efficacy. Vaginal estradiol 4 mcg showed a slightly greater improvement in cytology endpoints across separate studies, while prasterone provided a symptom-score reduction that was clinically meaningful with no detectable rise in serum estradiol. Neither finding can be treated as a definitive comparative claim in the absence of a head-to-head trial.

Safety Profiles and Contraindications

Prasterone. Because circulating estradiol stays within the postmenopausal range, prasterone does not require concurrent progestogen in women with an intact uterus, a position supported by the drug's FDA labeling. The most common adverse effect in trials was vaginal discharge, reported in 7.8 percent of prasterone users vs. 5.5 percent with placebo in ERC-230 [4]. Endometrial safety was evaluated in a 52-week biopsy substudy; no cases of endometrial hyperplasia occurred in the prasterone group [6]. For women with estrogen receptor-positive breast cancer history, prasterone's lack of systemic estrogen rise is the primary argument for its use, though no large prospective safety trial has yet enrolled this population exclusively.

Vaginal estradiol. Decades of observational and trial data support the safety of low-dose vaginal estradiol at standard doses. The Menopause Society states: "Low-dose vaginal estrogen therapy is safe for most menopausal women, and the available evidence does not support increased risk of breast cancer recurrence for women already treated for breast cancer who use low-dose vaginal estrogen" [1]. A 2019 JAMA Internal Medicine cohort study of 8,461 women with breast cancer found no statistically significant increase in recurrence risk associated with vaginal estrogen use (hazard ratio 1.08; 95% CI 0.87 to 1.34) [7]. Progestogen co-administration is generally not required at the 4-mcg tablet or low-dose cream doses because endometrial stimulation is minimal, though prescribers should review this on a case-by-case basis for women with an intact uterus using higher-dose preparations.

Both drugs share: no boxed warning when used in the approved vaginal formulations at low doses, though the package inserts carry class labeling language for estrogen-containing products.

Prasterone and Sexual Function Beyond Tissue Health

Vaginal estradiol restores tissue integrity and reduces pain with intercourse, but prasterone's androgenic component may offer additional effects on sexual desire and arousal. In ERC-230, the sexual function domain of the Menopause-Specific Quality of Life questionnaire showed statistically significant improvement with prasterone vs. placebo across desire, arousal, and orgasm subdomains [3]. This is a biologically plausible finding given androgen receptor density in clitoral and vaginal smooth muscle tissue.

Women asking about addyi vs vyleesi (flibanserin and bremelanotide, respectively) are asking about a different category: systemic drugs for hypoactive sexual desire disorder (HSDD), which is a libido condition rather than a tissue condition. GSM and HSDD can coexist. A woman with both vaginal atrophy and low libido might be a candidate for prasterone to address the tissue component while a separate evaluation for HSDD proceeds. Flibanserin (Addyi, 100 mg oral nightly) is FDA-approved for premenopausal HSDD; bremelanotide (Vyleesi, 1.75 mg subcutaneous injection as needed) is FDA-approved for premenopausal HSDD and carries a separate mechanism through melanocortin receptors [8].

Vaginal Estrogen vs Systemic HRT: When Local Therapy Is Not Enough

Women on systemic hormone therapy (oral estradiol, transdermal patch, or topical gel) sometimes still develop GSM symptoms because circulating estrogen does not always reach vaginal tissue in concentrations sufficient to reverse atrophy. A 2018 Cochrane review found that vaginal estrogen reduced vaginal dryness and dyspareunia more effectively than oral systemic therapy in direct comparisons, supporting the concept that local delivery provides targeted tissue concentrations that systemic routes may not match [9].

The reverse is equally true: women with GSM who also have significant vasomotor symptoms, bone density concerns, or mood disruption are candidates for systemic therapy first, with local vaginal therapy added if genitourinary symptoms persist. Prasterone has not been studied as an add-on to systemic estradiol; the theoretical concern is that adding intracellular estradiol production to already-elevated circulating estradiol creates an uncertain combined exposure. Vaginal estradiol at 4 mcg has been used alongside systemic therapy in clinical practice and in some registry data without documented safety signals, though prescribers typically document the decision and counsel patients accordingly.

Choosing Between Prasterone and Vaginal Estradiol: A Clinical Decision Framework

The choice between the two drugs depends on five patient-level factors.

1. Estrogen sensitivity history. Women with a personal history of estrogen-receptor-positive breast cancer, or with first-degree relatives and high-risk profiles on genetic panels, may prefer prasterone because serum estradiol does not rise above the postmenopausal baseline. The absence of a definitive prospective trial in breast cancer survivors makes either choice a shared decision with the oncologist.

2. Cost and formulary access. Prasterone (Intrarosa) lists near $380 per month without insurance. Generic vaginal estradiol 4-mcg tablets (Yuvafem, various generics) cost $30 to $80 per month with a GoodRx-style discount. Cost is a real barrier; a drug that is never dispensed treats nothing.

3. Desire for androgenic effects. Women who specifically report reduced arousal or difficulty with orgasm alongside vaginal dryness may benefit from prasterone's androgen component. Women whose primary complaint is tissue pain or dryness without a libido component do equally well with vaginal estradiol in clinical practice.

4. Applicator tolerance. Both drugs use an intravaginal applicator. Prasterone uses a pre-filled single-use applicator nightly. The 4-mcg estradiol tablet uses a small inserter twice weekly after a 2-week nightly loading phase. Women with severe dyspareunia at baseline may find the loading phase of vaginal estradiol uncomfortable; prasterone's nightly dosing during the initial weeks may feel equivalent in burden.

5. Concurrent systemic HRT. Vaginal estradiol at low doses is generally layered onto systemic therapy when GSM persists. The combination of prasterone plus systemic estradiol has not been formally studied and may produce combined intracellular and circulating estrogen effects that are not well characterized.

Formulations of Vaginal Estradiol Available in the United States

Vaginal estradiol comes in four delivery forms, each with a distinct pharmacokinetic profile.

The cream (Estrace Vaginal, generics) delivers 100 mcg estradiol per gram; the prescriber specifies gram-weight doses. Initial dosing is typically 2 to 4 g nightly for two weeks, then 1 g one to three times weekly for maintenance. Serum estradiol rises more with cream than with the insert, particularly at higher cream doses [10].

The 4-mcg insert (Vagifem, Yuvafem, generics) delivers the lowest systemic exposure of any prescription vaginal estradiol product. Nightly for 14 days, then twice weekly. REJOICE trial data showed most patients at postmenopausal estradiol levels (<20 pg/mL) throughout treatment [5].

The 10-mcg insert (older Vagifem, still prescribed) delivers roughly 2.5-fold more estradiol and carries slightly higher serum levels, though still classified as low-dose compared to systemic preparations.

The vaginal ring (Estring, 2 mg estradiol over 90 days) delivers approximately 7.5 mcg per 24 hours after an initial burst. Serum estradiol remains within the postmenopausal range at steady state. Many patients prefer the ring for its three-month wear cycle with no daily or twice-weekly application burden.

Practical Prescribing Timelines and Response Expectations

Both drugs require patience. Vaginal tissue does not remodel overnight. In ERC-230, the prasterone group showed statistically significant pH and cytology changes by week 4, but the full symptom benefit accumulated across all 12 weeks [3]. The same pattern appeared in REJOICE for vaginal estradiol: pH normalized early, but patient-reported dyspareunia continued improving through week 12 [5].

A reasonable clinical timeline: reassess at 8 to 12 weeks. If a patient reports minimal improvement at 8 weeks, confirm applicator technique before changing therapy. Incomplete drug deposition in the vaginal vault is a common, underreported cause of poor response. If technique is correct and symptoms persist at 12 weeks, consider switching formulation or adding a systemic component.

Women switching from vaginal estradiol to prasterone due to cost or breast cancer concerns should expect a 4-to-6-week overlap period in tissue response, since the tissue is losing direct estrogen stimulation and gaining intracellular DHEA-derived estrogen. No wash-out period is required pharmacokinetically.

Monitoring and Follow-Up

Neither drug requires routine endometrial monitoring in the absence of abnormal uterine bleeding when used at approved doses with intact-uterus patients. A 52-week biopsy study of prasterone (N=422) found zero cases of hyperplasia [6]. Low-dose vaginal estradiol carries the same benign endometrial record at standard doses in trial data extending to 52 weeks [5].

Vaginal pH testing at follow-up visits provides an objective, low-cost measure of tissue response. A pH below 5.0 suggests adequate estrogenization of the vaginal epithelium. A pH above 5.5 after 12 weeks of treatment warrants a review of adherence, technique, or diagnosis. The Menopause Society recommends annual reassessment of the continued need for therapy, though many women require indefinitely continued treatment because GSM symptoms return within weeks of stopping local therapy [1].